Europe Recombinant Protein Manufacturing Services Market Size Report, 2023-2032
The europe recombinant protein manufacturing services market size was estimated at USD 1.45 billion in 2022 and is expected to hit around USD 4.46 billion by 2032, poised to reach at a notable CAGR of 11.89% during the forecast period 2023 to 2032.
Key Takeaways:
Europe Recombinant Protein Manufacturing Services Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 1.62 Billion |
| Market Size by 2032 | USD 4.46 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 11.89% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Service type, host cell, end-use, country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Lonza; Boehringer Ingelheim International GmbH; FUJIFILM Diosynth Biotechnologies; Merck KGaA; Bruker (InVivo BioTech Services GmbH); Sino Biological, Inc.; GenScript; Kaneka corporation (Kaneka Eurogentec S.A); Polyplus Transfection (Xpress Biologics); Boster Biological Technology; Trenzyme GmbH |
The increasing outsourcing for recombinant protein manufacturing, the growing preference for biologics & biosimilars, the high prevalence of chronic disorders, and the increasing application of recombinant proteins are expected to boost market expansion. According to the European Society for Medical Oncology, an estimated 1,269,200 cancer deaths were reported in Europe in 2022. As recombinant proteins are widely used in research and diagnosis of cancer, an upsurge in the cancer burden is projected to boost the demand for proteins, driving market growth.
Moreover, the high burden of cancer creates a need for advanced therapeutics, leading to increased adoption of outsourcing services to produce advanced therapies such as recombinant proteins.
Recombinant protein production is a cost-intensive process that requires specialized facilities and large-scale production capabilities. Several challenges concerning regulatory compliance and adherence to manufacturing standards can further increase the complexities associated with the production of protein-based products. As a result, the trend toward outsourcing protein production to leverage the expertise and capabilities of CMOs in this domain has been increasing in recent years. Furthermore, certain specialized and repetitive activities, such as fill/finish, analytical testing/bioassays, and toxicology testing, are outsourced to a greater extent in the biopharmaceutical industry.
In the diagnostics domain, recombinant proteins find applications in immunoassays and molecular diagnostics for the detection & monitoring of various diseases. For instance, recombinant antigens and enzymes can be used for precise & sensitive identification of biomarkers and pathogens. Recombinant proteins are also increasingly used for industrial-scale applications. For instance, enzymes derived from recombinant DNA technology offer distinct advantages, such as enhanced efficacy, stability, and specificity, which makes them useful for the downstream processing of fermentation-based pharmaceutical products.
In addition, with the ongoing advancements in recombinant technology, novel applications of recombinant proteins for developing personalized medicine, cell & gene therapies, and bioengineering products are projected to increase. For instance, gene editing technologies, such as CRISPR-Cas9, have enabled the precise alteration of proteins to create innovative therapeutics. These factors are expected to significantly increase the demand for proteins, driving the market for manufacturing services.
Service Type Insights
Commercial production services was the largest revenue-generating segment with the dominant market share of 58.92% in 2022. The development of recombinant DNA technology, cell culture methods, protein expression systems, and growing accessibility of high-yield expression systems like mammalian cell lines, yeast, and bacteria, which can boost production productivity & efficiency, are some of the factors driving the commercial production services market.
The commercial production services segment is expected to witness the fastest CAGR of 16.39% over the forecast period due to an increasing focus on precision medicine, targeted therapies, and the growing need for outsourcing clinical trial design, data collection, & analysis. Moreover, Europe is home to some of the world’s high research and development (R&D) focused countries, such as the UK, Germany, and Denmark. For instance, according to EuroDev, the pharmaceutical industry in Germany spends over USD 6.74 billion (EUR 6.2 billion) annually on R&D and conducted around 499 clinical trials funded by research-based pharmaceutical companies in 2019. This is expected to drive market expansion throughout the forecast period.
Host Cell Insights
Mammalian host cell was the highest revenue-generating segment with the largest market share of 54.89% in 2022. For manufacturing complex proteins that need significant folding, subunit assembly, and/or posttranslational modifications, mammalian cells are fitting host cells. These features contribute to understanding the preference for mammalian cells utilized in the biotech and pharmaceutical sectors for manufacturing diagnostic and therapeutic proteins.
On the other hand, the yeast & fungi segment is estimated to witness a significant CAGR of 16.29% over the forecast period.Yeasts are now used in several healthcare fields, including the generation of therapeutic recombinant proteins and their traditional application in fermentation. Yeast cells are particularly captivating as hosts for biopharmaceutical synthesis as they are generally accepted as safe organisms. These factors are expected to drive market expansion throughout the forecast period.
End-use Insights
The pharmaceutical & biotechnology company segment held the largest market share of 78.89% in 2022. Numerous major and small biotechnology businesses are driving innovation in these fields in terms of service and manufacturing capabilities, providing commercial potential for market expansion. For instance, the EIB approved a USD 19.65 million (€18 million) investment to Estonian biotech Icosagen for new Current Good Manufacturing Practice (cGMP) production facilities and novel Research & Development (R&D) technologies. Furthermore, rising demand for protein manufacturing services, growing competition among players, and increasing biologics pipeline are contributing to the development of the global market.
On the other hand, the academic & research institutes industry segment is estimated to witness a 17.35% CAGR during the forecast period.As recombinant technology advances, novel uses of recombinant proteins enabling the development of customized medicine, cell and gene therapies, and bioengineering products are expected to grow at a rapid rate. For example, the development of gene editing technologies such as CRISPR-Cas9 permitted precise modification of recombinant proteins to develop novel therapies. These factors are projected to significantly improve the demand for recombinant proteins in academic and research institutes, driving the segment’s growth in the manufacturing services industry.
Country Insights
Germany held the dominant revenue share of 178.15% in 2022, attributed to increased research spending, the availability of well-established healthcare infrastructure, and the existence of several industry participants. These factors are expected to increase the demand for recombinant protein manufacturing services in the country.
The Netherlands is expected to experience the fastest CAGR of 21.95% over the forecast period due to improved healthcare infrastructure, improving economic factors, an increase in government efforts to raise awareness, as well as favorable regulatory policies that will boost the rate of adoption of manufacturing services. Furthermore, the region's increased need for high-quality healthcare has a favorable impact on the industry.
Some of the prominent players in the Europe Recombinant Protein Manufacturing Services Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Europe Recombinant Protein Manufacturing Services market.
By Service Type
By Host Cell
By End-use
By Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information analysis
1.2.2. Market formulation & data visualization
1.2.3. Data validation & publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Europe Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Increasing adoption of outsourcing models for recombinant protein manufacturing
3.3.2. The increasing scope of applications for recombinant protein-based products
3.3.3. Increasing the use of recombinant proteins in research-use activities
3.4. Market Restraint Analysis
3.4.1. Stringent regulations associated with recombinant protein-based biopharmaceuticals
3.5. Business Environment Analysis
3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.5.2. Porter’s Five Forces Analysis
3.6. COVID-19 Impact Analysis
Chapter 4. Service Type Business Analysis
4.1. Europe Recombinant Protein Manufacturing Services Market: Service Type Movement Analysis
4.2. Pre-clinical & Clinical Services
4.2.1. Pre-clinical & Clinical Services Market, 2020 - 2032
4.3. Commercial Production Services
4.3.1. Commercial Production Services Market, 2020 - 2032
Chapter 5. Host Cell Business Analysis
5.1. Europe Recombinant Protein Manufacturing Services Market: Host Cell Movement Analysis
5.2. Mammalian Cells
5.2.1. Mammalian Cells Market, 2020 - 2032
5.3. Bacterial Cells
5.3.1. Bacterial Cells Market, 2020 - 2032
5.4. Insect Cells
5.4.1. Insect Cells Market, 2020 - 2032
5.5. Yeast & Fungi
5.5.1. Yeast & Fungi Market, 2020 - 2032
5.6. Others
5.6.1. Others Market, 2020 - 2032
Chapter 6. End-use Business Analysis
6.1. Europe Recombinant Protein Manufacturing Services Market: End-use Movement Analysis
6.2. Pharmaceutical & Biotechnology Companies
6.2.1. Pharmaceutical & Biotechnology Companies Market, 2020 - 2032
6.3. Academic & Research Institutes
6.3.1. Academic & Research Institutes Market, 2020 - 2032
Chapter 7. Country Business Analysis
7.1. Europe Recombinant Protein Manufacturing Services Market Share By Country, 2022 & 2030
7.2. Europe
7.2.1. Europe Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.2. Germany
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. Target Disease Prevalence
7.2.2.5. Germany Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.3. UK
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Target Disease Prevalence
7.2.3.5. UK Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.4. France
7.2.4.1. Key Country Dynamics
7.2.4.2. Competitive Scenario
7.2.4.3. Regulatory Framework
7.2.4.4. Target Disease Prevalence
7.2.4.5. France Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.5. Italy
7.2.5.1. Key Country Dynamics
7.2.5.2. Competitive Scenario
7.2.5.3. Regulatory Framework
7.2.5.4. Target Disease Prevalence
7.2.5.5. Italy Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.6. Spain
7.2.6.1. Key Country Dynamics
7.2.6.2. Competitive Scenario
7.2.6.3. Regulatory Framework
7.2.6.4. Target Disease Prevalence
7.2.6.5. Spain Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.7. Denmark
7.2.7.1. Key Country Dynamics
7.2.7.2. Competitive Scenario
7.2.7.3. Regulatory Framework
7.2.7.4. Target Disease Prevalence
7.2.7.5. Denmark Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.8. Sweden
7.2.8.1. Key Country Dynamics
7.2.8.2. Competitive Scenario
7.2.8.3. Regulatory Framework
7.2.8.4. Target Disease Prevalence
7.2.8.5. Sweden Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.9. Norway
7.2.9.1. Key Country Dynamics
7.2.9.2. Competitive Scenario
7.2.9.3. Regulatory Framework
7.2.9.4. Target Disease Prevalence
7.2.9.5. Norway Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.10. Switzerland
7.2.10.1. Key Country Dynamics
7.2.10.2. Competitive Scenario
7.2.10.3. Regulatory Framework
7.2.10.4. Target Disease Prevalence
7.2.10.5. Switzerland Recombinant Protein Manufacturing Services Market, 2020 - 2032
7.2.11. Netherlands
7.2.11.1. Key Country Dynamics
7.2.11.2. Competitive Scenario
7.2.11.3. Regulatory Framework
7.2.11.4. Target Disease Prevalence
7.2.11.5. Netherlands Recombinant Protein Manufacturing Services Market, 2020 - 2032
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Profiles/Listing
8.3.1. Lonza
8.3.1.1. Overview
8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Boehringer Ingelheim International GmbH
8.3.2.1. Overview
8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. FUJIFILM Diosynth Biotechnologies
8.3.3.1. Overview
8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Merck KGaA
8.3.4.1. Overview
8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Bruker (InVivo BioTech Services GmbH)
8.3.5.1. Overview
8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Sino Biological, Inc.
8.3.6.1. Overview
8.3.6.2. Product Benchmarking
8.3.6.3. Strategic Initiatives
8.3.7. GenScript
8.3.7.1. Overview
8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Kaneka corporation (Kaneka Eurogentec S.A)
8.3.8.1. Overview
8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Polyplus Transfection (Xpress Biologics)
8.3.9.1. Overview
8.3.9.2. Product Benchmarking
8.3.9.3. Strategic Initiatives
8.3.10. Boster Biological Technology
8.3.10.1. Overview
8.3.10.2. Product Benchmarking
8.3.10.3. Strategic Initiatives
8.3.11. Trenzyme GmbH
8.3.11.1. Overview
8.3.11.2. Product Benchmarking
8.3.11.3. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers